About
Synfini, Inc., spun out of SRI International in 2023 and based in Menlo Park, California, combines neuro-symbolic AI with robotic wet-lab automation in its Agile Chemistry Foundry (SynRoute route planning, SynJet high-throughput screening, AutoSyn flow chemistry, SynBuild automated synthesis/purification) to compress small-molecule DMTA cycles for academic, biotech and pharma customers.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Synfini
Synfini, Inc., spun out of SRI International in 2023 and based in Menlo Park, California, combines neuro-symbolic AI with robotic wet-lab automation in its Agile Chemistry Foundry (SynRoute route planning, SynJet high-throughput screening, AutoSyn flow chemistry, SynBuild automated synthesis/purification) to compress small-molecule DMTA cycles for academic, biotech and pharma customers.
$53M
$53M
United States
BusinessLatest roundTotal raisedDate- Vivodyne
Robotic automation to produce human tissue for faster drug testing
Series A · $40M · 2025-05
$40M - Terray Therapeutics
Combines AI with wet lab science to discover new small-molecule drugs
Undisclosed · $120M · 2024-10
$120M - Excelsior Sciences
Machine-executable chemistry plus AI to speed small-molecule discovery and manufacturing; building the smart bloccs platform
Undisclosed · $70M · 2025-12
$70M
China
BusinessLatest roundTotal raisedDate- MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M - HOURS
AI chemical synthesis route and process design platform plus automated experimentation, for pharma CROs/CMOs and chemical and new energy materials companies
Undisclosed · 2026-09
— - Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
—
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M
Other / unspecified
BusinessLatest roundTotal raisedDate- Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health. Its Mahol-A-Ba platform brings AI and robotics into drug discovery, and its Astellas Venture Management unit makes early-stage biopharma investments
— - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 20 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.